Menopur (Menotrophin)

Menotrophin delivers both follicle‑stimulating hormone (FSH) and luteinizing hormone (LH) activity. After injection, the hormones bind to their respective receptors on ovarian cells, stimulating follicular growth, estrogen production, and the final maturation of the oocyte, ultimately leading to ovulation. The combined activity mimics the natural hormonal surge required for successful egg development.

The dose of Menopur is individualized and determined by the prescribing physician based on the patient’s ovarian response, treatment protocol, and clinical goals. The prescriber will calculate the appropriate number of international units (IU) per injection and adjust the regimen according to monitoring results such as ultrasound and hormone levels.

Menopur is intended for use before pregnancy to achieve conception. It is not recommended to continue treatment once pregnancy is confirmed, and it should be discontinued if pregnancy occurs. Safety data for use during breastfeeding are limited, so the medication is generally avoided in lactating women unless the benefits outweigh potential risks as assessed by a healthcare professional.

To order Menopur, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain logistics if needed), and any required import documentation.

The primary alternative to Menopur is recombinant FSH (e.g., Gonal‑F). Menopur provides both FSH and LH activity in a single preparation, which can simplify dosing for patients who need both hormones. Recombinant FSH offers a highly purified FSH‑only product, allowing separate LH supplementation if required. Choice between them depends on the treatment protocol, patient response, and physician preference.

Menopur must be stored refrigerated at 2‑8 °C (36‑46 °F). Keep the vials in the original packaging, protect them from light, and do not freeze or shake the solution. If the product reaches room temperature for a short period during administration, it may be used, but it should be returned to refrigeration promptly.

Menopur is supplied as a sterile injection solution for subcutaneous or intramuscular administration. The prescriber will instruct the patient on the injection site, technique, and dosing schedule. Typically, the medication is injected once daily, but the exact regimen is tailored to the individual’s response and the specific assisted‑reproductive protocol.

The most serious risks include ovarian hyperstimulation syndrome (OHSS), which can cause rapid ovarian enlargement, fluid shifts, and potentially life‑threatening complications; multiple pregnancy, increasing obstetric risk; ovarian torsion, presenting as acute pelvic pain; and severe allergic reactions such as anaphylaxis. Patients should be monitored closely for these events.

Menopur is contraindicated in women who are pregnant, have known hypersensitivity to menotrophin or any excipients, have ovarian cysts that could predispose to torsion, or have uncontrolled thyroid disease without appropriate management. It should also be avoided in patients with active ovarian cancer or severe ovarian hyperstimulation syndrome.